The document discusses GlaxoSmithKline's financial performance and forecasts, highlighting margin pressures, changes in core EPS forecasts, and strategic plans for growth. It includes a table comparing old and new core EPS forecasts from Deutsche Bank.
documents/vol00010-efta01457559-pdf.pdf
{"title":"Pharmaceuticals - GlaxoSmithKline","document_date":"2016-05-11","document_type":"tabular","key_organizations":["GlaxoSmithKline","Deutsche Bank"]}